也可用於 / Also available in:
简体中文 (Chinese (Simplified))
CD19-directed chimeric antigen receptor T cell (CART19) therapy is an immunotherapy that uses specifically altered T immune cells to attack tumor cells. Recently, reduced efficacy of CART19 therapy in chronic lymphocytic leukemia (CLL) patients is reported in the ASCO20 Virtual Scientific Program meeting. One of the key potential factors might be the inhibition of CART19 by CLL-EVs. By using A60 Apogee Micro-Plus, researchers found that an abundance of CLL B cells-derived EVs forming an immunosuppressive microenvironment which resulting in relatively lower durable response rates to CART cell therapy. it is hypothesized that EVs may potentially play a major role in the disruption of CART function based on the identifiable pre-clinical modulation of CART function. Learning the abundance of circulating EVs in the blood and circulating CART cells in the peripheral blood during CART cell expansion can give valuable data for new therapy development.
Reference:
- Cox, MJ et al., (2020). Leukemic Extracellular Vesicles Induce Chimeric Antigen Receptor T Cell Dysfunction in Chronic Lymphocytic Leukemia. Molecular Therapy. S1525-0016(20)30726-7. doi: 10.1016/j.ymthe.2020.12.033.
